SRPK1 and lung adenocarcinoma: These results reassured that regulation of SRPK1 was mediated by the methyltransferase catalytic function of METTL3, and suggested that STM2457 may be a promising clinical therapeutic strategy for patients with lung adenocarcinoma and extend the clinical usage of METTL3 inhibitors.